Sanofi, BioNTech cut early-stage mRNA cancer therapy from pipeline

Sanofi and BioN­Tech scrapped de­vel­op­ment of an mR­NA ther­a­py that can be in­ject­ed in­to a tu­mor af­ter see­ing re­sults from an in­ter­im analy­sis.

Sanofi on Fri­day dis­closed the de­vel­op­ment in its sec­ond quar­ter earn­ings re­port. The com­pa­nies first part­nered on a deal to de­vel­op can­cer im­munother­a­pies in 2015, and then in 2019, they put one can­di­date — SAR441000 — in a Phase I tri­al that en­rolled 77 pa­tients with ad­vanced sol­id tu­mors, clin­i­cal­tri­als.gov shows. The com­pa­nies were test­ing the can­di­date as a monother­a­py and as a com­bi­na­tion treat­ment with Sanofi and Re­gen­eron’s PD-1 check­point in­hibitor Lib­tayo.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN